Jump to content

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED


ShareCafe
 Share

Recommended Posts

FPH

 

ÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¬ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ Nice strong uptrend over last 4 months

ÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¬ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ Interesting action at moment with price hitting trend line. Possible a strong short term

bounce coming and long term trend continuing.

post-16-1088380780.png

Link to comment
Share on other sites

Fundamental Stats:

 

FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED [FPH]

 

Last Updated 15/06/2004

 

CORPORATE DETAILS

GICS Sector 35: Health Care

GICS Industry Group 3510: Health Care Equipment & Services

Head Office 15 Maurice Paykel Pl, East Tamaki, Auckland, 1701

Telephone + (649) 574 0100

Facsimile + (649) 574 0158

Website www.fphcare.co.nz

 

First Listed 21/11/2001

Balance Date 31 March

AGM 12/08/2004

 

Dividend Reinvestment? None

 

PRINCIPAL ACTIVITY

Fisher & Paykel Healthcare Corporation Limited (FPH) is involved in design,

manufacture and marketing of heated humidification products and systems for

respiratory care and treatment of obstructive sleep apnoea. FPH has an

international distribution network in the U.S, U.K, France, Germany, Australia

and NZ. Major clients are hospitals, home healthcare providers, distributors and

manufacturers of medical devices.

 

RESPIRATORY HUMIDIFICATION: FPH offers respiratory humidifiers, single-use and

reusable chambers, oxygen therapy supplies, breathing circuits and accessories.

Products are designed to humidify the gases that a patient receives during

mechanical ventilation, oxygen therapy or non-invasive ventilation. Products

include MR850 Respiratory Humidification System, MR410 Respiratory Humidifier

breathing circuits and components such as filters, catheter mount and weaning

kits and MR810 with simple controls and electronic thermostat.

 

OBSTRUCTIVE SLEEP APNOEA: FPH offers continuous positive air pressure (CPAP)

therapy products that are used in treatment of obstructive sleep apnoea to

prevent temporary airway closure during sleep. The products include chambers,

masks, integrated flow generator-humidifiers and are designed to deliver

humidified airflow to patients during CPAP therapy to prevent the disruption of

breathing during sleep. Range includes HC150 humidifier, HC220/221LE Integrated

Flow Generator Humidifier and convertible flow generators.

 

WARMING/NEONATAL PRODUCTS: Neonatal care products are designed to help maintain

normal body temperature for newborn babies. Infant resuscitators and continuos

positive airway pressure (CPAP) systems designed to improve infant respiratory

function. FPH also provides a range of radiant infrared warming products for

adults for pre, post and intra operative areas.

 

OTHER PRODUCTS: Fisher and Paykel also distribute breast pumps and the Doppler,

which is a Heart Monitor.

 

 

 

DIRECTORS

Prof Adrienne Elizabeth Clarke

Mr Michael G Daniell

Dr Nigel T Evans

Mr W Lindsay Gillanders

Sir Colin James Maiden

Mr Gary A Paykel

Mr P Michael Smith

 

 

Financial Stats:

 

FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

Health Care Equipment & Services

3510 Shares on Issue 101,955,628

 

Price: 1180

Market Cap: 1,203,076,410

Earnings: 46.2

Price To Earnings: 46.9442

Yield (%): 3.98

Asset Backing (cents per share): 148

Price to Assets: 7.97

 

Announcements:

25 Jun 2004 11:14:52 FPH Disclosure of Directors & Officers Relevant Interests ASXH

25 Jun 2004 11:14:38 Disclosure of Directors & Officers Relevant Interests

24 Jun 2004 08:32:25 FPH Daily Share Buy-Back Notice ASXH

24 Jun 2004 08:32:20 FPH Buy Back Update - Buy back of 50000 Ordinary Shares ASXH

24 Jun 2004 08:31:33 Daily Share Buy-Back Notice

24 Jun 2004 08:31:32 Buy Back Update - Buy back of 50000 Ordinary Shares

23 Jun 2004 08:30:38 Daily Share Buy-Back Notice

23 Jun 2004 08:30:35 News Release: Buy Back of 100 000 Ordinary Shares

21 Jun 2004 08:31:11 News Release: Opens Office in Japan

09 Jun 2004 12:45:00 Appendix 3B - 2001 Share Option Plan

09 Jun 2004 12:42:49 Notification of Issue of Securities

03 Jun 2004 14:16:37 Appendix 3B - 2001 Share Option Plan

03 Jun 2004 14:15:25 Notification of Issue of Securities

31 May 2004 11:55:28 Appendix 3B - Share Option Plan

31 May 2004 11:53:56 Notification of Issue of Securities

27 May 2004 08:31:03 Disclosure of Subsequent Director Relevant Interests

27 May 2004 08:31:02 Change of Directors Interest Notice

25 May 2004 14:53:50 Appendix 3B - 2001 Share Option Plan

25 May 2004 14:53:09 Notification of Issue of Securities

24 May 2004 08:35:44 FY04 Presentation to analysts and investment managers

20 May 2004 08:30:45 Preliminary Full Year Report

 

Link to comment
Share on other sites

  • 1 month later...
  • 16 years later...

Fisher & Paykel said that net profit after tax rose 82 per cent to $NZ524.2 million, after revenue rose 56 per cent to $1.97 billion.

 

The company’s directors have approved a final dividend of 22.0 cents per share, an increase of 42 per cent on the final dividend last year. The dividend will be paid on 7 July.

 

CEO Lewis Gradon said, “It has been an extraordinary yearâ€

 

The unprecedented result was driven by our hospital product group, which includes Optiflow and Airvo systems used to deliver nasal high flow therapy. Sales of our hospital hardware and consumables have continued to track COVID-19 hospitalisation surges in countries around the world.

 

In the financial year to date, hospital revenue continues to remain variable with higher volumes of hospital hardware and consumables to locations with hospitalisation surges and an ongoing shift towards Optiflow nasal high flow therapy. OSA shows signs of recovery after a slower fourth quarter.

 

With the ongoing uncertainties of vaccinations, lockdowns, COVID-19 variants, localised waves and return to stable hospitalisation rates around the world, the company is not providing guidance for the 2022 financial year.

 

The board has approved a profit-sharing bonus totalling $29 million for the 2021 financial year to be paid to everyone who has worked with us for a qualifying period.

 

 

Link to comment
Share on other sites

  • 5 months later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share

×
×
  • Create New...